In murine CD8+ T-cells, STAT3 has been shown to inhibit both IFN-γ-mediated CXCL10 production by myeloid cells and CD8+ T-cells CXCR3 expression (the receptor of CXCL10), blocking the migration of these cells to the tumor site [60]. Here, STAT3 is linked to neoplasm.